File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Novel therapeutic agents for T-cell lymphomas

TitleNovel therapeutic agents for T-cell lymphomas
Authors
Issue Date2013
PublisherSolariz, Inc. The Journal's web site is located at http://www.discoverymedicine.com
Citation
Discovery Medicine, 2013, v. 16 n. 86, p. 27-35 How to Cite?
AbstractT-cell lymphomas are a heterogeneous group of T-cell malignancies arising from post-thymic mature T-cells. Together they account for 10-15% of all non-Hodgkin's lymphoma. Because of the different underlying pathology, different T-cell lymphoma subtypes may require different treatment approaches. In general, the treatment results of T-cell lymphomas, using conventional anthracycline-based combination chemotherapy, are disappointing. Though autologous or allogeneic stem cell transplantation may offer a cure to some of the patients, a substantial proportion of patients are not eligible for transplantation because of the chemo-refractoriness or short remission duration of the lymphomas. Novel therapies may open up the potential path for better disease control. We review several classes of novel treatment for T-cell lymphomas including monoclonal antibodies, epigenetic modifiers, newer generation of cytotoxics, and specific targeting agents that may improve treatment outcome
Persistent Identifierhttp://hdl.handle.net/10722/203090
ISSN
2015 Impact Factor: 3.426
2015 SCImago Journal Rankings: 1.544

 

DC FieldValueLanguage
dc.contributor.authorChan, TSYen_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorTse, EWCen_US
dc.date.accessioned2014-09-19T11:29:49Z-
dc.date.available2014-09-19T11:29:49Z-
dc.date.issued2013en_US
dc.identifier.citationDiscovery Medicine, 2013, v. 16 n. 86, p. 27-35en_US
dc.identifier.issn1539-6509-
dc.identifier.urihttp://hdl.handle.net/10722/203090-
dc.description.abstractT-cell lymphomas are a heterogeneous group of T-cell malignancies arising from post-thymic mature T-cells. Together they account for 10-15% of all non-Hodgkin's lymphoma. Because of the different underlying pathology, different T-cell lymphoma subtypes may require different treatment approaches. In general, the treatment results of T-cell lymphomas, using conventional anthracycline-based combination chemotherapy, are disappointing. Though autologous or allogeneic stem cell transplantation may offer a cure to some of the patients, a substantial proportion of patients are not eligible for transplantation because of the chemo-refractoriness or short remission duration of the lymphomas. Novel therapies may open up the potential path for better disease control. We review several classes of novel treatment for T-cell lymphomas including monoclonal antibodies, epigenetic modifiers, newer generation of cytotoxics, and specific targeting agents that may improve treatment outcomeen_US
dc.languageengen_US
dc.publisherSolariz, Inc. The Journal's web site is located at http://www.discoverymedicine.com-
dc.relation.ispartofDiscovery Medicineen_US
dc.titleNovel therapeutic agents for T-cell lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL: ylkwong@hku.hken_US
dc.identifier.emailTse, EWC: ewctse@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityTse, EWC=rp00471en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros237441en_US
dc.identifier.volume16en_US
dc.identifier.issue86en_US
dc.identifier.spage27en_US
dc.identifier.epage35en_US
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats